A large NHS study published in the New England Journal of Medicine suggests a multi-cancer blood test can shift diagnoses away from late-stage disease, when treatment is hardest.
The NHS-Galleri trial, whose results appear in the *New England Journal of Medicine*, tested whether a single blood test could detect signals from multiple cancer types before symptoms appear. The trial found that screening led to more cancers being caught at an early stage, and a reduction in the most advanced (stage IV) diagnoses — though the study’s primary measure, a reduction in combined late-stage (stage III and IV) cancers, did not reach statistical significance. Notably, the trial did not meet its primary endpoint, a detail that the *NEJM* editorial’s tone of cautious interest reflects, and one that researchers and regulators will weigh carefully when considering any future rollout.
The *NEJM* also published an accompanying editorial, titled *A Step in the Search for the Elusive Holy Grail of Early Detection of Cancer*, reflecting the medical community’s cautious interest in what the findings might mean for population-level screening programmes. Early detection has long been one of oncology’s central goals, and a test capable of flagging multiple cancer types from a single blood draw would represent a meaningful shift in how screening could work.
Meanwhile, the trial carries the NHS name because it was run through NHS England, making it one of the largest real-world studies of this kind anywhere in the world.
But the research community is careful to note that publication in a peer-reviewed journal is not the same as a recommendation for routine use. Regulators and health bodies assess trial data before any test moves into standard NHS care, a process that can take considerable time after results are first published.
No date for any wider NHS rollout has been announced.
—
If you have concerns about cancer symptoms or want to discuss your screening options, contact your GP or call NHS 111. In an emergency, dial 999.
Source: @NEJM